OncoMark to Present Key Study on OncoMasTR Test for Early Stage Breast Cancer at ASCO 2019 in Chicago
Presentation will highlight superior clinical performance of the OncoMasTR test in Irish patients enrolled in the TAILORx Trial
Members of the OncoMark team will be attending the European Society of Medical Oncology 2018 Congress in Munich, Germany, from the 19th- 22nd October.
OncoMark Ltd are proud to announce the CE marking of the OncoMasTR test.
OncoMark today announced its declaration of conformity to the European In Vitro Diagnostic Directive 98/79/EC and CE mark of OncoMasTR, a gene expression profiling test for early-stage breast cancer prognosis.
OncoMark Ltd is pleased to announce that the company’s Quality Management System has been certified to ISO 13485:2016 by leading certification body, BSI.
OncoMark Announces Results of Key Studies on Clinical Performance of Prognostic Test for Early Stage Breast Cancer
OncoMark Ltd, an Irish diagnostics company, today announced the results of two key studies on the clinical performance of its OncoMasTR test.
OncoMark announce the appointment of Professor John Crown as the company’s Chief Medical Officer (CMO)
OncoMark Ltd, an Irish diagnostics company focused on the development of novel panels of cancer biomarkers to aid treatment decisions for cancer patients, today announced the appointment of Professor John Crown as the company’s Chief Medical Officer (CMO).
OncoMark to Present Two Studies on Prognostic Test for Early Stage Breast Cancer at ASCO 2018 in Chicago
Presentations will highlight the clinical performance of the OncoMasTR test in the TransATAC and TAILORx tissue bank cohorts
January 2018: OncoMark are attending the Arab Health Exhibition and Congress in Dubai
OncoMark CEO Mr. Des O’Leary and OncoMark Business Development Manager Mr. Fergus Fleming are attending the Arab Health Exhibition and Congress at the Dubai International Convention and Exhibition Centre from the 29th January to the 1st February 2018.